2015
Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes
Zeidan AM, Hendrick F, Friedmann E, Baer MR, Gore SD, Sasane M, Paley C, Davidoff AJ. Deferasirox therapy is associated with reduced mortality risk in a medicare population with myelodysplastic syndromes. Journal Of Comparative Effectiveness Research 2015, 4: 327-340. PMID: 26274794, PMCID: PMC5549705, DOI: 10.2217/cer.15.20.Peer-Reviewed Original ResearchConceptsMyelodysplastic syndromeMortality riskDeferasirox therapyOlder MDS patientsICD-9 codesIron chelation therapyEnd of studyMarginal structural modelsTransfusion thresholdMDS patientsMedicare patientsChelation therapyMedicare claimsMedicare populationPatientsBlood unitsAbstractTextTherapySignificant reductionSyndromeRiskWeeksMortality
2013
P-159 Lenalidomide performance in the real world: Patterns of utilization and effectiveness in a Medicare population with myelodysplastic syndromes
Zeidan A, Gore S, McNally D, Baer M, Hendrick F, Mahmoud D, Davidoff A. P-159 Lenalidomide performance in the real world: Patterns of utilization and effectiveness in a Medicare population with myelodysplastic syndromes. Leukemia Research 2013, 37: s95. DOI: 10.1016/s0145-2126(13)70207-8.Peer-Reviewed Original Research